These data translate to the in vivo setting, where ID8Trp53−/‐Brca1−/− and ID8Trp53−/‐Brca2−/− tumour‐bearing mice demonstrated increased survival after rucaparib treatment [13]. This evidence concerns the gene BRCA2 and neoplasm.